6794.TW UnicoCell Biomed Co., Ltd.

Healthcare Biotechnology Taiwan Stock Exchange
64.50 TWD
Close of Nov 6, 2026
63.50 93.20
Market cap
TWD 4.10B
P/E
-
P/B
5.01x
ROE
-11.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6794.TW undervalued?

Graham number

The Graham number of UnicoCell Biomed Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

UnicoCell Biomed Co., Ltd. fundamental analysis

No fundamental analysis for UnicoCell Biomed Co., Ltd. yet.

UnicoCell Biomed Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About UnicoCell Biomed Co., Ltd.

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing …

Full company profile